DMD Large equally mixed donor pool

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Choi, W.-S.
Right arrow Articles by Chang, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Choi, W.-S.
Right arrow Articles by Chang, K.

Vol. 29, Issue 7, 945-949, July 2001

SHORT COMMUNICATION
Pharmacokinetic Studies of 2-Amino-9-(3-acetoxymethyl-4-
isopropoxycarbonyl-oxybut-1-yl)purine, an Oral Prodrug for the Antiviral Agent Penciclovir

Won-Son Choi, Guang-Jin Im, Dae-Kee Kim, Tae-Kon Kim, Inho Jung, Taek-Soo Kim, Sung-Jae Lee, Namkyu Lee, Young-Woo Kim, Jae-Sun Kim, and Kieyoung Chang

Life Science Research Center,
SK Chemicals,
Suwon-Si, Korea

2-Amino-9-(3-acetoxymethyl-4-isopropoxycarbonyloxybut-1-yl)- purine (SK1899) was tested as an oral prodrug for penciclovir. SK1899 was administered orally to rats and dogs at doses up to 2 and 0.68 mmol/kg, respectively. SK1899 was well absorbed, and the major metabolites detected in plasma and urine were penciclovir, the active antiviral compound, and 6-deoxypenciclovir (M4) in both species. In rats, SK1899 was rapidly and extensively metabolized to penciclovir, which reached the peak plasma concentration (Cmax) of 39.5 µM at 0.5 h after 0.2-mmol/kg dosing. The area under the plasma concentration-time curve (AUC) for penciclovir was 57.5 µM · h. After an oral dose of 0.034 mmol/kg to dogs, extensive conversion of SK1899 to penciclovir also occurred with slower rate of formation of penciclovir from M4 than in rats. The mean Cmax and AUC for penciclovir were 4.5 µM at 2.7 h and 28.2 µM · h, respectively. The 0- to 24-h urinary recovery of penciclovir represented 36.1 and 36.3% of dose to rats and dogs, respectively. Radioactivity was found in fetuses following an oral administration of [14C]SK1899 to pregnant rats, but no significant accumulation was observed. Although substantial milk transfer of [14C]SK1899 occurred in rats, the radioactivity in milk was rapidly cleared. The values of Cmax, AUC, and urinary recovery of penciclovir after dosing with SK1899 to rats and dogs were similar or slightly higher than those from famciclovir. These data indicate that introduction of an isopropoxy carbonate group into one of the two hydroxyl groups of M4 did not significantly alter the oral bioavailability of penciclovir compared with famciclovir.


Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics






Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics.